Table 1. Demographic and treatment characteristics of the study population.

Characteristic	Survivors (N=404) N(%)	Siblings (N=4,022) N(%)
Sex
Male	213 (52.7)	1937 (48.2)
Female	191 (47.3)	2085 (51.8)
Race
White, non-Hispanic	377 (93.3)	3508 (87.2)
Black, non-Hispanic	6 (1.5)	112 (2.8)
Hispanic/Latino	12 (3.0)	148 (3.7)
Other	9 (2.2)	254 (6.3)
Age at diagnosis
<5 years	29 (7.2)
5-9 years	108 (26.7)
10-14 years	148 (36.6)
≥15 years	119 (29.5)
Year of diagnosis
1970-1974	57 (14.1)
1975-1979	146 (36.1)
1980-1986	201 (49.8)
Length of Follow-up*
5-9 years	57 (14.1)
10-14 years	35 (8.7)
15-19 years	31 (7.7)
20-24 years	99 (24.5)
≥25 years	182 (45.0)
Primary tumor site
Upper extremity	71 (17.6)
Lower extremity	144 (35.6)
Chest wall	53 (13.1)
Pelvis	65 (16.1)
Other**	55 (13.6)
Missing	16 (4.0)
Treatment Exposure
Chemotherapy only	8 (2.2)
Chemotherapy and radiation	140 (38.31)
Chemotherapy and surgery	62 (16.9)
Chemotherapy and radiation and surgery	134 (36.5)
Other***	23 (6.3)
Chest Radiotherapy
Yes	101 (28.5)
No	253 (71.5)
Median dose (range), Gy	34.5 (5.5 - 66.0)
Abdomen radiotherapy
Yes	47 (13.3)
No	307 (86.7)
Median dose (range) , Gy	40.0 (5.5 - 69.0)
Brain radiotherapy
Yes	23 (6.5)
No	331 (93.5)
Median dose (range) , Gy	45.0 (2.0 - 60.0)
Other head radiotherapy
Yes	15 (4.2)
No	339 (95.8)
Median dose (range) , Gy	45.0 (5.0 - 60.0)
Extremity radiotherapy
Yes	139 (39.3)
No	215 (60.7)
Median dose (range) , Gy	55.2 (10.0 - 112.0)
Total body irradiation
Yes	3 (0.8)
No	351 (99.2)
Median dose (range) , Gy	5.5 (5.0 - 8.0)
Alkylating agents
Yes	347 (96.9)
No	11 (3.1)
Median dose (range), mg/m2	14771.4 (11.3 - 51267.3)
Anthracycline
Yes	305 (85.2)
No	53 (14.8)
Median dose (range), mg/m2	382.8 (1.6 - 1070.0)

^*To the latest questionnaire or death, whichever is earlier

^**Diagnosis site code (C40.9, C41.9, C76.7, C80.9)

^***Twenty three survivors missing one or two of chemotherapy, RT, and surgery, and 1 patient had no chemotherapy or radiation only surgery